E P Hamilton
SCRI Development Innovations, LLC
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name E P Hamilton as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 11:07 UTC. Open this list on ClinicalTrials.gov
- Ph3NCT04906395 · Ovarian Suppression Evaluating Subcutaneous Leuprolide Acetate in Breast CancerTolmar Inc. · active not recruiting · Breast Cancer · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 11:07 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 132 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name in breast cancer, ranked by citations from NIH iCite, fetched 2026-11-12 11:07 UTC. The ranking covers the 200 most relevant of 15 PubMed records, and a shared surname and initials can bring in a namesake. All 15 on PubMed
- Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study.Breast Cancer Res Treat · 2018630 citationsRCR 20.9
- Datopotamab Deruxtecan in Advanced or Metastatic HR+/HER2- and Triple-Negative Breast Cancer: Results From the Phase I TROPION-PanTumor01 Study.J Clin Oncol · 2024176 citationsRCR 21.9
- 151 citationsRCR 31.3
- First-in-Human, Phase 1 Dose-Escalation Study of Biparatopic Anti-HER2 Antibody-Drug Conjugate MEDI4276 in Patients with HER2-positive Advanced Breast or Gastric Cancer.Mol Cancer Ther · 202193 citationsRCR 4.8
- A First-in-Human Study of the New Oral Selective Estrogen Receptor Degrader AZD9496 for ER+/HER2- Advanced Breast Cancer.Clin Cancer Res · 201867 citationsRCR 2.1
- Overall survival with abemaciclib in early breast cancer.Ann Oncol · 202666 citationsRCR 33.0
- Phase 1 Open-Label, Multicenter Study of First-in-Class RORγ Agonist LYC-55716 (Cintirorgon): Safety, Tolerability, and Preliminary Evidence of Antitumor Activity.Clin Cancer Res · 201953 citationsRCR 1.9
- Landscape of Baseline and Acquired Genomic Alterations in Circulating Tumor DNA with Abemaciclib Alone or with Endocrine Therapy in Advanced Breast Cancer.Clin Cancer Res · 202445 citationsRCR 4.8
- 45 citationsRCR 4.8
- Impact of Anti-HER2 Treatments Combined With Atezolizumab on the Tumor Immune Microenvironment in Early or Metastatic Breast Cancer: Results From a Phase Ib Study.Clin Breast Cancer · 202134 citationsRCR 1.6